Novozymes starts commercial supply of new and improved hyaluronic acid from Q7 cGMP facility
20:00 EDT 12 Aug 2012 | Pharma Asia
Novozymes Biopharma, part of Novozymes A/S, has announced the first shipment of the company’s Bacillus-derived hyaluronic acid, Hyasis, from its newly inaugurated manufacturing facility in China.
Original Article: Novozymes starts commercial supply of new and improved hyaluronic acid from Q7 cGMP facility
More From BioPortfolio on "Novozymes starts commercial supply of new and improved hyaluronic acid from Q7 cGMP facility"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
